- Home
- TBN vs RGNX Comparison
TBN vs RGNX Comparison
Compare TBN & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBN
- RGNX
- Stock Information
- Founded
- TBN 2009
- RGNX 2008
- Country
- TBN Australia
- RGNX United States
- Employees
- TBN N/A
- RGNX N/A
- Industry
- TBN
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TBN
- RGNX Health Care
- Exchange
- TBN NYSE
- RGNX Nasdaq
- Market Cap
- TBN 332.7M
- RGNX 387.0M
- IPO Year
- TBN 2024
- RGNX 2015
- Fundamental
- Price
- TBN $19.94
- RGNX $8.74
- Analyst Decision
- TBN Buy
- RGNX Strong Buy
- Analyst Count
- TBN 4
- RGNX 8
- Target Price
- TBN $35.00
- RGNX $31.75
- AVG Volume (30 Days)
- TBN 38.5K
- RGNX 1.0M
- Earning Date
- TBN 05-14-2025
- RGNX 07-31-2025
- Dividend Yield
- TBN N/A
- RGNX N/A
- EPS Growth
- TBN N/A
- RGNX N/A
- EPS
- TBN N/A
- RGNX N/A
- Revenue
- TBN N/A
- RGNX $156,718,000.00
- Revenue This Year
- TBN N/A
- RGNX $327.08
- Revenue Next Year
- TBN N/A
- RGNX N/A
- P/E Ratio
- TBN N/A
- RGNX N/A
- Revenue Growth
- TBN N/A
- RGNX 80.70
- 52 Week Low
- TBN $15.75
- RGNX $5.04
- 52 Week High
- TBN $34.50
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- TBN N/A
- RGNX 49.53
- Support Level
- TBN N/A
- RGNX $7.91
- Resistance Level
- TBN N/A
- RGNX $8.99
- Average True Range (ATR)
- TBN 0.00
- RGNX 0.65
- MACD
- TBN 0.00
- RGNX -0.05
- Stochastic Oscillator
- TBN 0.00
- RGNX 37.70
About TBN TAMBORAN RESOURCES CORPORATION
Tamboran Resources Corp is a gas company focused on supporting the Net Zero CO2 energy transition in Australia and Asia-Pacific through developing low CO2 unconventional gas resources in the Australian Northern Territory.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.